0.3696
price up icon3.97%   0.0141
 
loading
Schlusskurs vom Vortag:
$0.3555
Offen:
$0.3687
24-Stunden-Volumen:
1.46M
Relative Volume:
0.16
Marktkapitalisierung:
$26.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.08M
KGV:
-0.1713
EPS:
-2.1574
Netto-Cashflow:
$-72.06M
1W Leistung:
+5.60%
1M Leistung:
-28.51%
6M Leistung:
-71.79%
1J Leistung:
-60.68%
1-Tages-Spanne:
Value
$0.3411
$0.3734
1-Wochen-Bereich:
Value
$0.318
$0.3977
52-Wochen-Spanne:
Value
$0.2053
$2.79

Io Biotech Inc Stock (IOBT) Company Profile

Name
Firmenname
Io Biotech Inc
Name
Telefon
(457) 070-2980
Name
Adresse
OLE MAALOES VEH 3, COPENHAGEN
Name
Mitarbeiter
78
Name
Twitter
Name
Nächster Verdiensttermin
2025-08-08
Name
Neueste SEC-Einreichungen
Name
IOBT's Discussions on Twitter

Compare IOBT vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IOBT
Io Biotech Inc
0.3696 25.58M 0 -86.08M -72.06M -2.1574
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
491.47 117.98B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
803.17 82.85B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
821.96 51.58B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
314.40 40.75B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.07 38.33B 4.98B 69.60M 525.67M 0.5198

Io Biotech Inc Stock (IOBT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-01-26 Herabstufung Piper Sandler Overweight → Neutral
2026-01-08 Herabstufung Morgan Stanley Equal-Weight → Underweight
2025-09-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-09-30 Herabstufung TD Cowen Buy → Hold

Io Biotech Inc Aktie (IOBT) Neueste Nachrichten

pulisher
07:16 AM

Will IO Biotech Inc. outperform its industry peers2025 Technical Overview & Free Real-Time Volume Trigger Notifications - mfd.ru

07:16 AM
pulisher
Feb 13, 2026

IO Biotech Faces Nasdaq Noncompliance, Potential Delisting Risk - TipRanks

Feb 13, 2026
pulisher
Feb 13, 2026

IO Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Feb 13, 2026
pulisher
Feb 13, 2026

Nasdaq warns IO Biotech (NASDAQ: IOBT) on $50M market value rule - Stock Titan

Feb 13, 2026
pulisher
Feb 13, 2026

Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing - Finviz

Feb 13, 2026
pulisher
Feb 12, 2026

Is IO Biotech Inc. a top pick in the sectorJuly 2025 Catalysts & Short-Term High Return Ideas - mfd.ru

Feb 12, 2026
pulisher
Feb 09, 2026

Layoff Tracker: Delayed Notice Reveals 141 More Layoffs From Genentech in 2025 - BioSpace

Feb 09, 2026
pulisher
Feb 06, 2026

Guidance Update: Is IO Biotech Inc in a consolidation phaseJuly 2025 PostEarnings & Safe Capital Growth Tips - baoquankhu1.vn

Feb 06, 2026
pulisher
Feb 05, 2026

Fierce Biotech Layoff Tracker 2026: ARPA-H makes cuts; GSK trims R&D team - Fierce Biotech

Feb 05, 2026
pulisher
Feb 02, 2026

IO Biotech Provides Corporate Update - marketscreener.com

Feb 02, 2026
pulisher
Feb 02, 2026

IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Recommendation of “Reduce” from Analysts - Defense World

Feb 02, 2026
pulisher
Jan 30, 2026

IO Biotech (IOBT) launches restructuring, CMO exit and up to $2.6M charges - Stock Titan

Jan 30, 2026
pulisher
Jan 30, 2026

IO Biotech hires Raymond James as advisor, cuts workforce By Investing.com - Investing.com Canada

Jan 30, 2026
pulisher
Jan 30, 2026

IO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction and Cost-Containment Measures - Quiver Quantitative

Jan 30, 2026
pulisher
Jan 30, 2026

Cancer vaccine maker IO Biotech cuts staff, hires Raymond James - Stock Titan

Jan 30, 2026
pulisher
Jan 27, 2026

Piper downgrades IO Biotech amid strategic alternatives evaluation - Yahoo Finance

Jan 27, 2026
pulisher
Jan 26, 2026

IO Biotech stock tumbles after Piper Sandler downgrades on strategic review By Investing.com - Investing.com South Africa

Jan 26, 2026
pulisher
Jan 26, 2026

IO Biotech stock tumbles after Piper Sandler downgrades on strategic review - Investing.com South Africa

Jan 26, 2026
pulisher
Jan 26, 2026

Piper Sandler Downgrades IO Biotech (IOBT) to Neutral, Lowers Pr - GuruFocus

Jan 26, 2026
pulisher
Jan 26, 2026

Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3 - marketscreener.com

Jan 26, 2026
pulisher
Jan 26, 2026

IO Biotech stock rating downgraded by Piper Sandler amid strategic review - Investing.com South Africa

Jan 26, 2026
pulisher
Jan 25, 2026

IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why - MSN

Jan 25, 2026
pulisher
Jan 25, 2026

Aug Decliners: Is IO Biotech Inc a potential multi baggerMarket Growth Report & Entry and Exit Point Strategies - baoquankhu1.vn

Jan 25, 2026
pulisher
Jan 23, 2026

IOBT IO Biotech, Inc. (NASDAQ) $0.47 on 22 Jan 2026: active intraday mover for traders - Meyka

Jan 23, 2026
pulisher
Jan 22, 2026

IO Biotech’s Future Uncertain As Cylembio Cloud Remains - Citeline News & Insights

Jan 22, 2026
pulisher
Jan 22, 2026

IO Biotech Begins Review Of Strategic Options As Cash Runway Narrows - Nasdaq

Jan 22, 2026
pulisher
Jan 22, 2026

IO Biotech weighs strategic options months after FDA advises against melanoma vaccine filing - European Biotechnology Magazine

Jan 22, 2026
pulisher
Jan 22, 2026

IO Biotech admits defeat | ApexOncoClinical Trials news and analysis - Oncology Pipeline

Jan 22, 2026
pulisher
Jan 22, 2026

Listed Danish biotech company fights for survival after FDA rejection and failed capital raising - medwatch.com

Jan 22, 2026
pulisher
Jan 22, 2026

IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36% - Intellectia AI

Jan 22, 2026
pulisher
Jan 21, 2026

Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow - Nasdaq

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech stock plummets after company explores strategic alternatives By Investing.com - Investing.com Nigeria

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech stock plummets after company explores strategic alternatives - Investing.com

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech announces exploration of strategic alternatives - TipRanks

Jan 21, 2026
pulisher
Jan 21, 2026

IO mulls more layoffs months after halving head count in wake of cancer vaccine setback - Fierce Biotech

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech Explores Strategic Alternatives Amid Cost-Cutting Plans - TipRanks

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech (IOBT) Explores Strategic Alternatives to Maximize Shareholder Value - Intellectia AI

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech, Inc. Announces Exploration of Strategic Alternatives - TradingView

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech to explore strategic alternatives - MSN

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech Announces Exploration of Strategic Alternatives - The Manila Times

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech Announces Exploration of Strategic Alternatives to Enhance Stockholder Value - Quiver Quantitative

Jan 21, 2026
pulisher
Jan 21, 2026

Moderna cancer vaccine holds up; IO Biotech considers a sale - Yahoo Finance

Jan 21, 2026
pulisher
Jan 21, 2026

Cancer vaccine developer weighs sale, merger or liquidation - Stock Titan

Jan 21, 2026
pulisher
Jan 21, 2026

IO Biotech Explores Strategic Alternatives to Maximize Shareholder Value - Intellectia AI

Jan 21, 2026
pulisher
Jan 18, 2026

Merger Talk: Does IO Biotech Inc align with a passive investing strategy2025 Technical Patterns & Verified Swing Trading Watchlist - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 18, 2026

Market Review: How do insiders feel about SOPAWeekly Stock Report & Real-Time Stock Entry Alerts - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 17, 2026

Market Trends: What is the long term forecast for IO Biotech Inc stockJuly 2025 Momentum & Fast Gain Swing Trade Alerts - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 17, 2026

Valuation Update: Can ALCY lead its sector in growthWeekly Trade Recap & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 17, 2026

IO Biotech receives Nasdaq notice for bid price noncompliance - MSN

Jan 17, 2026
pulisher
Jan 16, 2026

Jefferies maintains IO Biotech Buy rating, $8 target on PFS hopes - MSN

Jan 16, 2026
pulisher
Jan 16, 2026

IO Biotech Faces Existential Threats as Funding and Regulatory Woes Mount - AD HOC NEWS

Jan 16, 2026

Finanzdaten der Io Biotech Inc-Aktie (IOBT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$26.45
price down icon 1.12%
$45.19
price up icon 0.87%
$101.10
price up icon 0.35%
$105.87
price up icon 0.10%
$148.75
price up icon 1.77%
biotechnology ONC
$346.07
price down icon 0.10%
Kapitalisierung:     |  Volumen (24h):